

Les conférences FR TransBioMed

Invitation : Isabelle Vigon – Inserm U1035

Emmanuel Sarry

Team leader at the Cancer Research Center of Toulouse
Team 18 – Drug Resistance & Oncometabolism in Acute Myeloid Leukemia
Centre de Recherches en Cancérologie de Toulouse - CRCT
UMR1037 Inserm/Université Toulouse III-Paul Sabatier

“Mitochondrial metabolism and flexibility in acute myeloid leukemia”

Mardi 21 mai à 11h00

Salle de conférences de l'IBGC - site de Carreire zone sud,
université de Bordeaux

Despite a high rate of complete remission after treatment with genotoxic agents, the prognosis is poor in human acute myeloid leukemia (AML), due to frequent relapses caused by resistant leukemic clones (RLCs). Our goal is to understand the causes of the drug resistance for the development of new treatments eradicating RLCs and overcoming patient relapses. Here we will discuss about the role of mitochondrial oxidative metabolism in drug resistance of AML and about newly-identified metabolic features of patients harboring mutations in key metabolic enzymes isocitrate dehydrogenases.

Jean-Emmanuel Sarry is a Team Leader and a Principal Investigator in Hemato-Oncology at Inserm. Dr. Sarry received his PhD degree in Biochemistry from the University of Montpellier. He also completed his scientific training in Plant and Yeast Metabolism at the Department of Plant Physiology (CEA, Grenoble) and at the Department of Biology (University of Pennsylvania, Philadelphia), respectively. After studying the phenotypic heterogeneity of leukemic stem cells at University of Pennsylvania Medical School, he joined the Cancer Research Center of Toulouse in 2010. The major focus of his laboratory's research is the role of oncometabolism and mitochondria in drug resistance of acute myeloid leukemia using a combination of biochemistry, omics approaches and innovative preclinical models.